Aller au contenu principal
Accès ouvert déclaré 2026 article

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment

0Citations signalées, ce qui n’est pas une note de qualité
7Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract Background and Objective MRI‐targeted biopsies (TBx) combined with systematic biopsies (SBx) have traditionally been recommended for patients with unilateral MRI‐suspicious prostate cancer (PCa) lesions. Recent European Association of Urology (EAU) guidelines propose that, in cases with a solitary lesion, TBx with perilesional sampling may suffice, potentially omitting contralateral SBx. The clinical impact of this omission remains uncertain. This study evaluates how omitting contralateral SBx affects pathological grading, EAU risk classification, and estimated lymph node involvement (LNI). Methods We conducted a retrospective cohort study (2016–2024) including 190 biopsy‐naïve men diagnosed with PCa via TBx and bilateral SBx for a single, unilateral MRI‐visible lesion. Outcomes were re‐evaluated using only TBx and ipsilateral SBx, simulating omission of contralateral SBx. Changes in ISUP grade, EAU risk group, and LNI probability using the Briganti 2019, Amsterdam–Brisbane–Sydney (ABS), and Memorial Sloan Kettering Cancer Center (MSKCC) nomograms were assessed. Furthermore, we compared cancer detection rates for TBx alone versus TBx plus ipsilateral SBx. Key Findings ISUP grading changed in 14 of 190 patients (7.4%) when contralateral SBx was omitted; two patients (1.1%) had clinically significant PCa (ISUP 2) detected solely in contralateral cores. In seven patients (3.7%), only ISUP 1 cancer was found in contralateral SBx, meaning no diagnosis would have been made without those cores. EAU risk classification changed in five patients (2.6%). LNI estimates were affected minimally: One patient (0.5%) dropped below the Briganti 7% threshold, and one patient (1.2%) no longer met the 8% ABS threshold. The MSKCC model showed a statistically significant 8% increase in patients above the 7% ePLND threshold when contralateral SBx was omitted ( p = 0.0023). Ipsilateral SBx substantially improved detection of higher‐grade disease: sensitivity for ISUP ≥3 increased from 82% with TBx alone to 98% when combined with ipsilateral SBx. Conclusion and Clinical Implications Omitting contralateral SBx in patients with unilateral MRI lesions had limited effect on grading, risk classification, and LNI estimates. However, ipsilateral SBx adds significant diagnostic value compared with TBx alone and should be retained. These findings support a more targeted diagnostic approach in patients with a unilateral lesion on MRI in a primary diagnostic setting.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
Date Crossref
01/02/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Prostate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchMRI in cancer diagnosis

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.